Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Gains from Sales and Divestitures (2019 - 2020)

Pliant Therapeutics (PLRX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $163568.0 as the latest value for Q4 2020.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $163568.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $163568.0, a N/A change, with the full-year FY2020 number at $163568.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $163568.0 for Q4 2020 at Pliant Therapeutics, up from $130257.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $335610.0 in Q3 2019 to a low of $92199.0 in Q2 2020.